Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Severe Hemophilia A
Interventions
DRUG

Nuwiq

Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

Trial Locations (18)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Unknown

RECRUITING

University Hospital Centre Zagreb, Zagreb

RECRUITING

Helsinki University Hospital, Helsinki

RECRUITING

CHU de Nantes Hôtel-Dieu, Nantes

RECRUITING

CHRU de Tours, Tours

RECRUITING

Vivantes Klinikum im Friedrichshein (KFH), Berlin

RECRUITING

Gerinnungszentrum Rhein-Ruhr, Duisburg

RECRUITING

Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg

RECRUITING

Christian Medical College Vellore, Vellore

NOT_YET_RECRUITING

St. John's Medical College Hospital, Bengaluru

RECRUITING

Azienda Ospedaliera Pugliese Ciaccio, Catanzaro

RECRUITING

Azienda Ospedaliero Universitaria Careggi - Centro Emofilia, Florence

RECRUITING

Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital, Milan

RECRUITING

Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia, Skopje

RECRUITING

Clinical Center for Serbia Belgrade, Belgrade

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

Hospital Universitario Virgen del Rocio, Seville

NOT_YET_RECRUITING

St. James's University Hospital, Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT05935358 - Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | Biotech Hunter | Biotech Hunter